Studying Biomarkers in Blood Samples From Patients With Invasive Cervical Cancer

Development of a Serum Proteomic Profile for Cervical Cancer With Potential Prognostic Value

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01074424

Enrollment

Registered

2010-02-24

Start date

2010-02-28

Completion date

Unknown

Last updated

2010-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer

Keywords

stage IIB cervical cancer, stage III cervical cancer, stage IVA cervical cancer, cervical adenocarcinoma, cervical adenosquamous cell carcinoma, cervical squamous cell carcinoma

Brief summary

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors predict how well patients will respond to treatment. PURPOSE: This research study is looking at biomarkers in blood samples from patients with invasive cervical cancer.

Detailed description

OBJECTIVES: Primary * To develop a serum proteomic profile for cervical cancer using banked pre-treatment serum specimens from patients with invasive cervical cancer and to determine if this serum proteomic profile has possible utility in cervical cancer prognosis. Secondary * To develop a serum proteomic profile for cervical cancer using banked post-treatment serum specimens from these patients and to determine if this serum proteomic profile has possible utility in cervical cancer prognosis. OUTLINE: This is a multicenter study. Banked serum specimens are used to generate proteomic profiles.

Interventions

GENETICproteomic profiling

OTHERlaboratory biomarker analysis

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Inclusion criteria

DISEASE CHARACTERISTICS: * Histologically confirmed invasive adenocarcinoma, squamous cell carcinoma, or adenosquamous cell carcinoma of the cervix * Stage IIB, III, or IVA disease * Eligible and evaluable for GOG-0191 * Pre- and/or post-treatment serum specimens available for proteomic analysis PATIENT CHARACTERISTICS: * Patient has given consent to allow their specimen(s) to be used for future cancer research PRIOR CONCURRENT THERAPY: * See Disease Characteristics

Design outcomes

Primary

Measure	Time frame
Generation of a serum proteomic profile using banked pre-treatment serum specimens that may have potential utility for cervical cancer prognosis (overall survival and progression-free survival [PFS])	—

Secondary

Measure	Time frame
Generation of a serum proteomic profile using banked post-treatment serum specimens that may have potential utility for cervical cancer prognosis (overall survival and PFS)	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026